Literature DB >> 176620

Massive-dose progestational therapy in oncology (medroxyprogesterone). Preliminary results.

F Pannuti, A Martoni, E Pollutri, P Camera, F Losinno, H Giusti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 176620

Source DB:  PubMed          Journal:  Panminerva Med        ISSN： 0031-0808            Impact factor:   5.197


× No keyword cloud information.
  3 in total

1.  High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy.

Authors:  M De Lena; C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer.

Authors:  G N Hortobagyi; A U Buzdar; D Frye; H Y Yap; V Hug; K Pinnamaneni; G Fraschini; H C Halvorson; G R Blumenschein
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

3.  Medroxyprogesterone acetate: steady-state pharmacokinetics bioequivalence of two oral formulations.

Authors:  K Pollow; R Kreienberg; N Di Pietro
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.